Axiom Exhibiting at Clinical Operations in Oncology Trials West Coast 2023
25 avr. 2023 13h13 HE
|
Axiom Real-Time Metrics Inc
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations,...
Lifeist’s Mikra Announces Successful Study Results for CELLF
13 avr. 2023 07h06 HE
|
Lifeist Wellness Inc.
TORONTO, April 13, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCQB: LFSWF), a health-tech company that leverages advancements in...
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
28 mars 2023 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
22 mars 2023 08h09 HE
|
CytoSorbents
PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
20 mars 2023 08h28 HE
|
Revive Therapeutics Ltd.
TORONTO, March 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Baptist Cancer Center research proves incidental lung nodule program effective in detecting cancer early
09 mars 2023 08h00 HE
|
Baptist Memorial Health Care
Memphis, TN, March 09, 2023 (GLOBE NEWSWIRE) -- Memphis-based Baptist Cancer Center published a JAMA Network Open article proving the effectiveness of incidental lung nodule, or tumor, programs in...
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
27 févr. 2023 08h30 HE
|
Imunon, Inc.
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON,...
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
01 févr. 2023 19h14 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV)...
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
17 janv. 2023 08h30 HE
|
SciSparc Ltd
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. ...
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
09 janv. 2023 08h30 HE
|
SciSparc Ltd
Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ...